



Atty. Dkt. No. 072121-0189

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jang HAN et al.
Title: MODIFIED SMALL INTERFERING RNA MOLECULES AND
METHODS OF USE
Appl. No.: 10/626,879
Filing Date: July 25, 2003
Examiner: Jane J. ZARA
Art Unit: 1635
Confirmation Number: 1049

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 C.F.R. §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

11/24/2006 SZEWDIE1 00000102 10626879

02 FC:1806

180.00 OP

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 C.F.R. §1.97(c), before the mailing date of either a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 C.F.R. §1.17(p) to cover the fee associated with an information disclosure statement under 37 C.F.R. §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

November 22, 2006

By

Richard C. Peet

FOLEY & LARDNER LLP

Customer Number: 27476

Telephone: (202) 672-5483

Facsimile: (202) 672-5399

Richard C. Peet

Attorney for Applicant

Registration No. 35,792



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 17, 2006 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/626,879
		Filing Date	July 25, 2003
		First Named Inventor	Jang Han
		Art Unit	1635
		Examiner Name	Jane J. ZARA
Sheet	1	of	1
		Attorney Docket Number	072121-0189

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A1	BLAIR-PARKS et al., "High-level gene transfer to the cornea using electroporation," <i>J. Gene Med.</i> , 4(1): 92-1000 (Jan.-Feb. 2002).	
	A2	CAPODICI et al., "Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference," <i>The Journal of Immunology</i> , pages 5196-5201, November 1, 2002.	
	A3	GE et al., "RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription," <i>Proc. Natl. Acad. Sci. USA</i> , 100(5):2718-23 (Mar. 2003).	
	A4	LEWIS et al., "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>Nat. Genet.</i> , 32(1):107-08 (Sept. 2002).	
	A5	MARTIN et al., "Gene transfer to intact mesenteric arteries by electroporation," <i>J. Vasc. Res.</i> , 37(5):372-80 (Sept.-Oct. 2000).	
	A6	SMITH et al., "Advances in plasmid gene delivery and expression in skeletal muscle," <i>Curr. Opin. Mol. Ther.</i> , 2(2):150-54 (Apr. 2000).	
	A7	SONG et al., "RNA interference targeting Fas protects mice from fulminant hepatitis," <i>Nat. Med.</i> , 9(3):347-51 (Mar. 2003).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.